𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea

✍ Scribed by Byung Chul Yoo; Joong-Won Park; Hyung Joon Kim; Dong Ho Lee; Young Ju Cha; Sill Moo Park

Book ID
118564841
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
92 KB
Volume
38
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evolution of precore/core promoter mutat
Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion
✍ Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Prof. Jia-Horng Kao; Ding-Shinn Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

## Abstract The evolution of precore stop codon mutation (A1896) and dinucleotide mutation (T1762/A1764) in the basic core promoter (BCP) of hepatitis B virus (HBV) genome during transient seroconversion and seroreversion of hepatitis B e antigen (HBeAg) remains unclarified. Five HBeAg‐positive HBV

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Precore/core promoter mutations and geno
Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis
✍ Chun-Jen Liu; Jia-Horng Kao; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Abstract The association of precore stop codon mutation (A1896), dinucleotide mutation (T1762/A1764) in the basic core promoter of hepatitis B virus (HBV) genome, and genotype of HBV with fulminant or subfulminant hepatitis remains controversial. We studied HBV genotypes as well as mutations in